Key result
Type 2 diabetes is linked to ~2-fold higher treatment costs compared to controls without diabetes.
Why the study?
What is the economic burden of type 2 diabetes management in France compared to controls without diabetes?
Observational
What is the economic burden of type 2 diabetes management in France compared to controls without diabetes?
The economic burden of treating T2D in France is double that of non-diabetic controls, highlighting the need for expanded access to new treatments to reduce costly complications.
The cost of treating patients with T2D is almost double that of controls without diabetes. However, the overall costs of treating diabetes in 2022 appear to be stable compared with 2013. Expanding access to new treatments and technologies could help improve clinical outcomes in T2D, potentially leading to reductions in costly complications. There is a need for improved health policies for people living with T2D in the overseas departments.
No takes yet. Share an insight, caveat, or question.
Guerci et al. (2026) conducted an observational in Type 2 diabetes. Type 2 diabetes vs. controls without diabetes was evaluated on cost of treating patients. Type 2 diabetes was associated with almost double the treatment costs compared to controls without diabetes, though overall costs in 2022 appeared stable compared with 2013.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: